Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?

Detalles Bibliográficos
Autores principales: Peng, Ling, Stebbing, Justin, Liang, Fei, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512471/
https://www.ncbi.nlm.nih.gov/pubmed/34733635
http://dx.doi.org/10.21037/tlcr-21-650
_version_ 1784582999043473408
author Peng, Ling
Stebbing, Justin
Liang, Fei
Xia, Yang
author_facet Peng, Ling
Stebbing, Justin
Liang, Fei
Xia, Yang
author_sort Peng, Ling
collection PubMed
description
format Online
Article
Text
id pubmed-8512471
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85124712021-11-02 Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end? Peng, Ling Stebbing, Justin Liang, Fei Xia, Yang Transl Lung Cancer Res Letter to the Editor AME Publishing Company 2021-09 /pmc/articles/PMC8512471/ /pubmed/34733635 http://dx.doi.org/10.21037/tlcr-21-650 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Letter to the Editor
Peng, Ling
Stebbing, Justin
Liang, Fei
Xia, Yang
Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
title Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
title_full Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
title_fullStr Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
title_full_unstemmed Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
title_short Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
title_sort dual immune checkpoint blockade for non-small cell lung cancer patients with pd-l1 high expression: calling an end?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512471/
https://www.ncbi.nlm.nih.gov/pubmed/34733635
http://dx.doi.org/10.21037/tlcr-21-650
work_keys_str_mv AT pengling dualimmunecheckpointblockadefornonsmallcelllungcancerpatientswithpdl1highexpressioncallinganend
AT stebbingjustin dualimmunecheckpointblockadefornonsmallcelllungcancerpatientswithpdl1highexpressioncallinganend
AT liangfei dualimmunecheckpointblockadefornonsmallcelllungcancerpatientswithpdl1highexpressioncallinganend
AT xiayang dualimmunecheckpointblockadefornonsmallcelllungcancerpatientswithpdl1highexpressioncallinganend

Ejemplares similares